--- title: "Leo Pharma Considers IPO as It Moves Toward Public Listing" type: "News" locale: "en" url: "https://longbridge.com/en/news/279063787.md" description: "Leo Pharma is preparing for a potential IPO, engaging investment bankers for its public listing. This strategic move aims to enhance its market presence and financial capabilities, particularly in dermatology. While details on timing and size are not disclosed, the IPO could provide capital for research and development, reflecting broader trends in the pharmaceutical sector seeking public investment for innovation. Stakeholders will monitor the company's IPO strategy closely." datetime: "2026-03-13T14:49:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279063787.md) - [en](https://longbridge.com/en/news/279063787.md) - [zh-HK](https://longbridge.com/zh-HK/news/279063787.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/279063787.md) | [繁體中文](https://longbridge.com/zh-HK/news/279063787.md) # Leo Pharma Considers IPO as It Moves Toward Public Listing Leo Pharma is reportedly preparing for a potential initial public offering (IPO), according to sources familiar with the matter. Bloomberg posted on X that the Danish pharmaceutical company, which has been in operation for over a century, is engaging investment bankers to compete for roles in the anticipated public listing. The move marks a significant step for Leo Pharma as it explores options to expand its market presence and financial capabilities. The company, known for its dermatology products, is considering this strategic shift amid evolving industry dynamics and market opportunities. While specific details regarding the timing and size of the IPO remain undisclosed, the decision underscores Leo Pharma's ambition to enhance its growth trajectory and leverage public market resources. The potential IPO could provide the company with increased capital to support its research and development initiatives and expand its global footprint. Leo Pharma's exploration of a public listing reflects broader trends in the pharmaceutical sector, where companies are increasingly seeking public investment to fuel innovation and competitiveness. As the company moves forward with its plans, stakeholders and industry observers will be closely monitoring developments related to its IPO strategy. ### Related Stocks - [ProShares UltraShort Nasdaq Biotech (BIS.US)](https://longbridge.com/en/quote/BIS.US.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/en/quote/512010.CN.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md) - [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/en/quote/159892.CN.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/en/quote/510660.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/en/quote/588130.CN.md) - [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md) - [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) ## Related News & Research - [Centre may bar cancelled drug licence holders from seeking fresh approvals](https://longbridge.com/en/news/281649968.md) - [Clover Biopharmaceuticals Completes Enrollment in Phase 2 Trial for Combination Respiratory Vaccines](https://longbridge.com/en/news/280923090.md) - [08:33 ETDrugwatch Investigation Reveals Big Pharma Profits Continue to Outpace Billions in Legal Penalties](https://longbridge.com/en/news/281368752.md) - [Stocks in Play: Ventripoint Diagnostics Ltd](https://longbridge.com/en/news/281544776.md) - [Cloudbreak Pharma's 2025 Loss Narrows](https://longbridge.com/en/news/281317115.md)